EJC Supplements
Volume 5, Issue 2 , Pages 49-59 , July 2007

Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients

  • Raoul Herbrecht

      Affiliations

    • Département d’Hématologie et d’Oncologie, Hôpital de Hautepierre, 67098 Strasbourg, France
    • Corresponding Author InformationCorresponding author: Tel.: +33 388 12 76 88; fax: +33 388 12 76 81.
    • ,
  • Ursula Flückiger

      Affiliations

    • Universitätsspital Basel, Basel, Switzerland
    • ,
  • Bertrand Gachot

      Affiliations

    • Institut Gustave Roussy, Villejuif, France
    • ,
  • Patricia Ribaud

      Affiliations

    • Hôpital Saint Louis, Paris, France
    • ,
  • Anne Thiebaut

      Affiliations

    • Hôpital Edouard Herriot, Lyon, France
    • ,
  • Catherine Cordonnier

      Affiliations

    • Hôpital Henri Mondor, Créteil, France

Received 14 May 2007 ,Revised 8 June 2007 ,Accepted 11 June 2007.

References 

  1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415
  2. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366:1435–1442
  3. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33:139–144
  4. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of haematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122–1128
  5. Viscoli C, Girmenia C, Marinus A, et al. Candidaemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28:1071–1079
  6. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274–1277
  7. White MH. The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis. 1997;24:1129–1130
  8. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149–3154
  9. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis. 2005;41:975–981
  10. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764–771
  11. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322:579–582
  12. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly. 2002;132:316–320
  13. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943–951
  14. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54:803–808
  15. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205–212
  16. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B colloidal dispersion for treatment of candidaemia in immunocompromised patients. Clin Infect Dis. 1998;26:461–467
  17. Ito JI, Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis. 2005;40(Suppl 6):S384–S391
  18. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964–972
  19. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of haematogenous candidiasis: a matched cohort study. Am J Med. 1996;101:170–176
  20. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidaemia. Am J Med. 1998;104:238–245
  21. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidaemia in non-neutropenic patients. Canadian Candidaemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16:337–345
  22. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. Candidaemia Study Group and the National Institute. N Engl J Med. 1994;331:1325–1330
  23. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:651–655
  24. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234
  25. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020–2029
  26. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402
  27. DiNubile MJ, Hille D, Sable CA, Kartsonis NA. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect. 2005;50:443–449
  28. Ruhnke M, Kuse E, Chetchotisakd P, Arns da Cunha C, Diekmann-Berndt H. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16–19; 2005 [Abstract M-722c].
  29. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T. Anidulafungin vs. fluconazole for treatment of candidaemia and invasive candidiasis. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16–19; 2005 [Abstract M718].
  30. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161–189
  31. Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidaemia? An evidence-based review. Clin Infect Dis. 2002;34:591–599
  32. Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidaemia. Clin Infect Dis. 2004;38:1119–1127
  33. SFAR, SPILF, SRLF, Société Française d’Hématologie, Société Française de Mycologie Médicale, Société Française de Greffe de Moelle. Management of invasive candidiasis and aspergillosis in adults. Rev Pneumol Clin 2004;60:289–93.
  34. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82(Suppl 2):S133–S140
  35. Gavalda J, Ruiz I. Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin. 2003;21:498–508
  36. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis. 2004;48:153–160
  37. Antoniadou A, Torres HA, Lewis RE, et al. Candidaemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore). 2003;82:309–321
  38. Baddley JW, Patel M, Jones M, Cloud G, Smith AC, Moser SA. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidaemia. Diagn Microbiol Infect Dis. 2004;50:119–124
  39. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother. 2000;44:2715–2718
  40. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 1998;177:425–430
  41. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988;84:826–832
  42. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidaemia. NIAID Mycoses Study Group and the Candidaemia Study Group. Antimicrob Agents Chemother. 1995;39:40–44
  43. Wenisch C, Moore CB, Krause R, Presterl E, Pichna P, Denning DW. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol. 2001;39:2458–2462
  44. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidaemia. Antimicrob Agents Chemother. 2005;49:3171–3177
  45. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol. 2006;44:819–826
  46. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med. 2000;160:2659–2664
  47. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002;112:380–385
  48. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28:873–878
  49. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359–366
  50. Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27:1406–1412
  51. Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal Amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood. 2005;106:[Abstract 3222]
  52. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173–180
  53. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608–615
  54. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366
  55. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79:250–260
  56. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother. 2001;45:3487–3496
  57. Cordonnier C, Bresnik M, Ebrahimi R. Liposomal amphotericin B efficacy in invasive filamentous fungal infections: Pooled analysis. In: Proceeding of the 44th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), October 30–November 2; 2004 [Abstract M-1022].
  58. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 1997;19:343–347
  59. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383–1396
  60. Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2005;40(Suppl 6):S392–S400
  61. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155–1163
  62. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135–144
  63. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis. 2001;33:e83–e90
  64. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–571
  65. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122–1131
  66. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106:2641–2645
  67. Mouas H, Lutsar I, Dupont B, et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis. 2005;40:1141–1147
  68. Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–198
  69. Walsh TJ, Patterson T, Langston A, et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Blood. 2003;102:195a
  70. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–1571
  71. Kartsonis NA, Saah AJ, Joy LC, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect. 2005;50:196–205
  72. Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol. 2005;75:227–233
  73. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18:163–194
  74. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukaemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025–1032
  75. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–299
  76. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin combined with other antifungals in adults with invasive aspergillosis refractory or intolerant to prior therapy: final results. In: Proceeding of the 45th interscience conference on antimicrobial agents and chemotherapy, Washington (DC), December 16–19; 2005 [Abstract M-954].
  77. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802
  78. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother. 2001;45:1456–1462
  79. Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother. 2000;45:85–93
  80. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother. 1998;42:282–288
  81. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997;40:401–414
  82. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998;42:497–502
  83. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol. 2000;49:601–606
  84. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305–319

☆ The ECIL-1 is a common initiative of the following groups or organisations: Infectious Diseases Working Party of the European Blood and Marrow Transplantation Group (EBMT-IDWP), Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), European Leukemia Net (ELN) (EU Grant number: LSHC-CT-2004), and International Immunocompromised Host Society (ICHS).

PII: S1359-6349(07)00009-2

doi: 10.1016/j.ejcsup.2007.06.007

EJC Supplements
Volume 5, Issue 2 , Pages 49-59 , July 2007

Article Tools

* Image Usage & Resolution